Distant metastasis-free survival proportions with 95% confidence intervals for all subtypes, by surrogate classifier, in STO-3a
| Subtyping method and follow-up time point . | Luminal A Survival proportion % (95% CI) . | Luminal B Survival proportion % (95% CI) . | HER2 Survival proportion % (95% CI) . | Basal-like Survival proportion % (95% CI) . |
|---|---|---|---|---|
| PAM50 | ||||
| 5 y | 95.8 (93.6 to 98.1) | 78.8 (71.8 to 86.6) | 80.1 (70.2 to 91.3) | 81.2 (71.7 to 91.8) |
| 10 y | 90.4 (87.2 to 93.8) | 68.6 (60.6 to 77.7) | 70.2 (59.0 to 83.6) | 73.5 (62.8 to 86.0) |
| IHC3 | ||||
| 5 y | 91.4 (88.8 to 94.1) | 70.0 (52.5 to 93.3) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 84.0 (80.6 to 87.6) | 65.0 (47.1 to 89.7) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallen14 | ||||
| 5 y | 94.1 (91.1 to 97.3) | 86.9 (82.7 to 91.4) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 88.3 (84.1 to 92.7) | 78.7 (73.5 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallen20 | ||||
| 5 y | 93.4 (90.4 to 96.6) | 87.0 (82.5 to 91.7) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 88.1 (84.1 to 92.4) | 78.0 (72.5 to 83.9) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallenfree | ||||
| 5 y | 92.6 (89.5 to 95.8) | 87.4 (82.7 to 92.3) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 86.5 (82.4 to 90.8) | 78.9 (73.1 to 85.1) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Prolif14 | ||||
| 5 y | 92.2 (89.4 to 95.1) | 84.6 (78.0 to 91.9) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 85.8 (82.2 to 89.6) | 75.2 (67.2 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Prolif20/Proliffree | ||||
| 5 y | 91.4 (88.6 to 94.3) | 85.1 (76.9 to 94.1) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 85.3 (81.8 to 89.0) | 72.5 (62.4 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Subtyping method and follow-up time point . | Luminal A Survival proportion % (95% CI) . | Luminal B Survival proportion % (95% CI) . | HER2 Survival proportion % (95% CI) . | Basal-like Survival proportion % (95% CI) . |
|---|---|---|---|---|
| PAM50 | ||||
| 5 y | 95.8 (93.6 to 98.1) | 78.8 (71.8 to 86.6) | 80.1 (70.2 to 91.3) | 81.2 (71.7 to 91.8) |
| 10 y | 90.4 (87.2 to 93.8) | 68.6 (60.6 to 77.7) | 70.2 (59.0 to 83.6) | 73.5 (62.8 to 86.0) |
| IHC3 | ||||
| 5 y | 91.4 (88.8 to 94.1) | 70.0 (52.5 to 93.3) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 84.0 (80.6 to 87.6) | 65.0 (47.1 to 89.7) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallen14 | ||||
| 5 y | 94.1 (91.1 to 97.3) | 86.9 (82.7 to 91.4) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 88.3 (84.1 to 92.7) | 78.7 (73.5 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallen20 | ||||
| 5 y | 93.4 (90.4 to 96.6) | 87.0 (82.5 to 91.7) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 88.1 (84.1 to 92.4) | 78.0 (72.5 to 83.9) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallenfree | ||||
| 5 y | 92.6 (89.5 to 95.8) | 87.4 (82.7 to 92.3) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 86.5 (82.4 to 90.8) | 78.9 (73.1 to 85.1) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Prolif14 | ||||
| 5 y | 92.2 (89.4 to 95.1) | 84.6 (78.0 to 91.9) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 85.8 (82.2 to 89.6) | 75.2 (67.2 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Prolif20/Proliffree | ||||
| 5 y | 91.4 (88.6 to 94.3) | 85.1 (76.9 to 94.1) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 85.3 (81.8 to 89.0) | 72.5 (62.4 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
CI = confidence interval; IHC = immunohistochemistry; STO-3 = Stockholm tamoxifen trial.
Distant metastasis-free survival proportions with 95% confidence intervals for all subtypes, by surrogate classifier, in STO-3a
| Subtyping method and follow-up time point . | Luminal A Survival proportion % (95% CI) . | Luminal B Survival proportion % (95% CI) . | HER2 Survival proportion % (95% CI) . | Basal-like Survival proportion % (95% CI) . |
|---|---|---|---|---|
| PAM50 | ||||
| 5 y | 95.8 (93.6 to 98.1) | 78.8 (71.8 to 86.6) | 80.1 (70.2 to 91.3) | 81.2 (71.7 to 91.8) |
| 10 y | 90.4 (87.2 to 93.8) | 68.6 (60.6 to 77.7) | 70.2 (59.0 to 83.6) | 73.5 (62.8 to 86.0) |
| IHC3 | ||||
| 5 y | 91.4 (88.8 to 94.1) | 70.0 (52.5 to 93.3) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 84.0 (80.6 to 87.6) | 65.0 (47.1 to 89.7) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallen14 | ||||
| 5 y | 94.1 (91.1 to 97.3) | 86.9 (82.7 to 91.4) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 88.3 (84.1 to 92.7) | 78.7 (73.5 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallen20 | ||||
| 5 y | 93.4 (90.4 to 96.6) | 87.0 (82.5 to 91.7) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 88.1 (84.1 to 92.4) | 78.0 (72.5 to 83.9) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallenfree | ||||
| 5 y | 92.6 (89.5 to 95.8) | 87.4 (82.7 to 92.3) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 86.5 (82.4 to 90.8) | 78.9 (73.1 to 85.1) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Prolif14 | ||||
| 5 y | 92.2 (89.4 to 95.1) | 84.6 (78.0 to 91.9) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 85.8 (82.2 to 89.6) | 75.2 (67.2 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Prolif20/Proliffree | ||||
| 5 y | 91.4 (88.6 to 94.3) | 85.1 (76.9 to 94.1) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 85.3 (81.8 to 89.0) | 72.5 (62.4 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Subtyping method and follow-up time point . | Luminal A Survival proportion % (95% CI) . | Luminal B Survival proportion % (95% CI) . | HER2 Survival proportion % (95% CI) . | Basal-like Survival proportion % (95% CI) . |
|---|---|---|---|---|
| PAM50 | ||||
| 5 y | 95.8 (93.6 to 98.1) | 78.8 (71.8 to 86.6) | 80.1 (70.2 to 91.3) | 81.2 (71.7 to 91.8) |
| 10 y | 90.4 (87.2 to 93.8) | 68.6 (60.6 to 77.7) | 70.2 (59.0 to 83.6) | 73.5 (62.8 to 86.0) |
| IHC3 | ||||
| 5 y | 91.4 (88.8 to 94.1) | 70.0 (52.5 to 93.3) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 84.0 (80.6 to 87.6) | 65.0 (47.1 to 89.7) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallen14 | ||||
| 5 y | 94.1 (91.1 to 97.3) | 86.9 (82.7 to 91.4) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 88.3 (84.1 to 92.7) | 78.7 (73.5 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallen20 | ||||
| 5 y | 93.4 (90.4 to 96.6) | 87.0 (82.5 to 91.7) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 88.1 (84.1 to 92.4) | 78.0 (72.5 to 83.9) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| St. Gallenfree | ||||
| 5 y | 92.6 (89.5 to 95.8) | 87.4 (82.7 to 92.3) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 86.5 (82.4 to 90.8) | 78.9 (73.1 to 85.1) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Prolif14 | ||||
| 5 y | 92.2 (89.4 to 95.1) | 84.6 (78.0 to 91.9) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 85.8 (82.2 to 89.6) | 75.2 (67.2 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
| Prolif20/Proliffree | ||||
| 5 y | 91.4 (88.6 to 94.3) | 85.1 (76.9 to 94.1) | 86.5 (73.3 to 100.0) | 79.9 (71.0 to 89.9) |
| 10 y | 85.3 (81.8 to 89.0) | 72.5 (62.4 to 84.2) | 70.8 (53.5 to 93.8) | 76.7 (67.3 to 87.4) |
CI = confidence interval; IHC = immunohistochemistry; STO-3 = Stockholm tamoxifen trial.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
